Search
News
Heritage Global Q2 2026 Earnings: HGC Exit Drives a US$15.9 Million Net Loss
Heritage Global’s Q2 2026 revenue fell 14.3% to US$12.3 million, while diluted EPS swung to a US$0.46 loss from a US$0.05 profit. The company recorded approximately US$21.7 million of noncash impairment and credit-loss charges as it substantially winds down Heritage Global Capital, producing a US$15.9 million net loss. Adjusted EBITDA remained positive at US$1.2 million but declined from US$2.8 million, while cash and working capital fell from December levels.
TradingKey
Thu, Aug 13
GrabAGun Q2 2026 earnings: Margin gains were outweighed by higher expenses
GrabAGun’s Q2 2026 revenue rose 9.4% to $23.2 million, while gross margin expanded 290 basis points to 13.5% as average order value increased and firearms mix shifted toward higher-priced products. However, the company reported a $1.8 million net loss and diluted EPS of -$0.06, compared with $0.8 million of net income and $0.08 a year earlier, as operating expenses increased. Firearms and non-firearms sales both grew, PEW Logistics began contributing service revenue, and cash remained $97.5 million despite negative first-half operating cash flow.
TradingKey
Thu, Aug 13
Veritone Q2 2026 earnings: Revenue rises as gross margin contracts
Veritone’s fiscal Q2 2026 revenue rose 4.6% year over year to $24.3 million, but GAAP gross margin fell to 58.5% from 67.5% as lower-margin revenue became a larger part of the mix. The company posted a $22.2 million net loss, narrower than $26.5 million a year earlier, while its operating loss widened to $22.1 million due largely to $4.5 million of restructuring costs. Total ARR was $62.0 million, with falling SaaS ARR offset by higher consumption ARR, and Veritone issued full-year revenue guidance of $100 million to $115 million.
TradingKey
Thu, Aug 13
Co-Diagnostics Q2 2026 Earnings: Losses Narrow as Revenue Stays Near $0.17 Million
Co-Diagnostics’ Q2 2026 revenue was $166,131, up about 2% year over year, while GAAP net loss narrowed to $6.28 million and loss per share improved to $1.46 from $7.00. Operating expenses fell 23% to $6.32 million, helping reduce the operating loss, but gross margin declined to about 72.7%. Cash ended the quarter at $3.65 million, down from $11.88 million at year-end, as CODX continued funding regulatory studies, manufacturing expansion, and commercialization work for its still-uncleared Co-Dx PCR platform.
TradingKey
Thu, Aug 13
Vuzix Q2 2026 earnings: Revenue fell as operating cash use increased
Vuzix reported Q2 2026 revenue of $1.1 million, down 14% year over year, while loss per share narrowed to $0.09 from $0.10. The gross loss improved, but liquidity pressure increased as operating cash use rose to $6.6 million from $4.8 million. Product and engineering-services sales both declined despite customer milestones involving Amazon, Collins Aerospace, a global automaker and Augmex. Continued R&D and waveguide-manufacturing investment remains central to Vuzix’s strategy, making commercialization progress and cash consumption the main issues to monitor.
TradingKey
Thu, Aug 13
HawkEye 360 Q2 2026 earnings: Revenue grows 87% but GAAP profitability reverses
HawkEye 360 reported Q2 2026 revenue of $49.8 million, up 87% year over year, while diluted EPS swung to a $0.07 loss from $0.01 profit. International revenue reached a record $21.0 million, but higher operating costs pushed the company to a $15.3 million GAAP net loss and reduced adjusted EBITDA to $7.0 million. Quarterly free cash flow improved to $5.4 million, and the May IPO lifted cash and cash equivalents to $503.4 million. Full-year guidance calls for $215 million to $220 million in revenue.
TradingKey
Thu, Aug 13
AudioEye Q2 2026 Earnings: Adjusted EBITDA Reaches a Record $3.0 Million
AudioEye’s Q2 2026 earnings showed revenue rising 9% year over year to a record $10.7 million, while adjusted EBITDA increased to a record $3.0 million from $1.9 million. GAAP net loss widened to $0.9 million, or $0.07 per share, as the prior-year quarter benefited from a $1.4 million contingent-consideration gain and current litigation costs increased. ARR reached $42.3 million, up 11% year over year. The company raised full-year adjusted EBITDA guidance to at least $12.7 million while projecting 2026 revenue of $43.5 million to $44.0 million.
TradingKey
Thu, Aug 13
MultiSensor AI Q2 2026 Earnings: Software Growth Narrows Losses
MultiSensor AI’s Q2 2026 revenue increased 19% to $1.7 million, led by an 85% rise in software revenue to $0.7 million, while net loss narrowed 26% to $2.5 million. Diluted loss per share improved to $1.19 from $3.96, although the larger weighted-average share count contributed to that change. Lower costs improved operating leverage, but six-month operating cash outflow edged up to $4.1 million as receivables grew. Cash ended June at $21.0 million, with a 10-site rollout planned for the second half.
TradingKey
Thu, Aug 13
NeuroOne Fiscal Q3 2026 Earnings: Gross Margin Expands as Net Loss Widens
NeuroOne’s fiscal Q3 2026 product revenue rose 16% to $2.0 million, while product gross margin expanded to a record 59.9% from 53.9%. The company’s net loss widened to $2.0 million from $1.5 million as operating expenses increased to $3.6 million. New product orders reached $2.7 million, exceeding quarterly recognized revenue and lifting backlog to $1.7 million, but cash and working capital declined from fiscal year-end levels as NeuroOne continued funding sales, development, and commercialization activities, with no debt at quarter-end.
TradingKey
Thu, Aug 13
NextPlat Q2 2026 Earnings: Gross Margin Reaches 40% as Loss Narrows
NextPlat’s Q2 2026 revenue was $11.9 million, down about 10% year over year but up 21% sequentially. Gross margin reached approximately 40%, compared with 22% a year earlier, as higher-margin 340B and medication fulfillment services improved the healthcare mix. Net loss attributable to common stockholders narrowed to $144,000, or $0.05 per diluted share, from $1.8 million, or $0.69 per share. Contracted pharmacy revenue rose 136% to $2.2 million, while total pharmacy prescription revenue declined amid lower reimbursement rates and payer mix.TradingKey
Thu, Aug 13
ADC Therapeutics Q2 2026 Earnings: Lower Spending Narrows the Loss
ADC Therapeutics’ Q2 2026 results showed total revenue of $19.2 million, including $18.6 million in net product revenue, while GAAP loss per share narrowed to $0.11 from $0.50. Total operating expenses fell 29% to $44.7 million, led by lower R&D and restructuring costs, and net loss improved to $16.6 million from $56.6 million. Cash was $219.1 million as of June 30, with runway expected at least into 2028. However, FDA concerns about LOTIS-5’s benefit-risk profile leave ZYNLONTA’s full-approval path under review.
TradingKey
Thu, Aug 13
McGraw Hill Fiscal Q1 2027 Earnings: Margin Expansion Outpaces Revenue Growth
McGraw Hill (NYSE: MH) reported fiscal first quarter 2027 revenue of $549.9 million, up 2.6% year over year, while diluted EPS rose to $0.30 from $0.00. GAAP gross margin expanded 290 basis points to 79.9%, and adjusted EBITDA increased 8.2% to $207.0 million. Higher Education led segment growth with a 9.6% revenue increase, while K-12 grew 1.3%. Operating cash flow improved to $0.6 million from a $96.7 million outflow, though cash declined as product development and capital spending continued.
TradingKey
Thu, Aug 13
VENU Fiscal Q2 2026 Earnings: Asset Growth Raises Financing Demands
VENU’s fiscal Q2 2026 earnings release showed six-month revenue of $8.5 million, up 7%, while the six-month net loss widened to $34.2 million and operating cash use improved to $9.4 million. Total assets reached $511.8 million at June 30, up 38% from year-end, as property and equipment climbed to $446.2 million amid heavy venue construction. The key issue is financing: capital spending drove a $25.0 million cash decline, while VENU raised equity and other funding and outlined more than $150 million of post-quarter C-PACE financing.
TradingKey
Thu, Aug 13
Accelerant Q2 2026 Earnings: Exchange Premium Rises 23%
Accelerant (NYSE: ARX) reported Q2 2026 total revenue of $356.9 million, up about 63% year over year, while diluted EPS rose to $0.36 from $0.04. Exchange Written Premium increased 23% to $1.32 billion, and adjusted EBITDA reached $93.1 million with a 30.6% margin. Growth was supported by a larger third-party premium mix, although $53.0 million of investment gains amplified GAAP results. The company also disclosed negative first-half operating cash flow and withheld forward guidance following its pending Thoma Bravo acquisition agreement.
TradingKey
Thu, Aug 13
Stratasys Q2 2026 Earnings: Record Consumables Amid Flat Revenue
Stratasys (NASDAQ: SSYS) reported Q2 2026 revenue of $137.6 million, down about 0.3% year over year but up 3.7% sequentially. GAAP net loss was $16.9 million, or $0.19 per diluted share, while non-GAAP EPS held at $0.03. Record consumables revenue of $66.3 million and 17% aerospace and defense growth supported the quarter, but adjusted EBITDA fell to $5.3 million and operating cash use rose to $18.7 million. The company reaffirmed most 2026 guidance while withdrawing its expectation for positive full-year operating cash flow.
TradingKey
Thu, Aug 13
Buda Juice Q2 2026 Earnings: Revenue Growth Came With Margin Pressure
Buda Juice’s Q2 2026 earnings showed revenue rising 26.4% to $4.5 million, while gross margin fell to 36.6% from 46.7% and free cash flow was negative $0.8 million. Same-store beverage growth, distribution into 246 Walmart stores and acquired dressings operations supported sales. Temporary co-packing, elevated lime and freight costs, training investments and a higher public-company cost base pressured profit. The company ended June debt-free, while preliminary net sales for the first six weeks of Q3 increased more than 40% year over year.
TradingKey
Thu, Aug 13
Nomad Foods Q2 2026 earnings: Gross margin improves despite lower volume
Nomad Foods’ Q2 2026 revenue fell 3.1% to €723.7 million as a 5.9% volume decline outweighed a 3.0% price-mix benefit. Adjusted gross margin rose 110 basis points to 28.9% on pricing and supply-chain productivity, but adjusted EBITDA declined 4.3% to €123.7 million and adjusted EPS slipped to €0.39. Reported profit also fell 15%. The company maintained its organic revenue, EBITDA and cash-conversion outlooks while lowering full-year adjusted EPS guidance to €1.38-€1.53 because of higher interest expense following recently completed refinancing and higher variable interest rates.
TradingKey
Thu, Aug 13
Applied Industrial Technologies Q4 FY2026 earnings: Organic growth lifts EBITDA margin
Applied Industrial Technologies reported fiscal Q4 2026 net sales of $1.353 billion, up 10.4% year over year, with organic growth of 9.7%. Diluted EPS increased 13.2% to $3.17, while non-GAAP EBITDA rose 16.1% to $177.6 million and margin expanded by roughly 60 basis points. Engineered Solutions led segment growth, though Service Center produced the larger margin gain. Fiscal 2027 guidance calls for 4.0% to 6.5% total sales growth, EPS of $11.65 to $12.15, and a 12.5% to 12.8% EBITDA margin.
TradingKey
Thu, Aug 13
SBC Medical Q2 2026 Earnings: Revenue Reaccelerates as Margins Expand
SBC Medical’s fiscal Q2 2026 revenue rose 13% year over year to $49.2 million, while basic and diluted EPS increased to $0.10 from $0.02. Net income attributable to the company reached $10.7 million, and adjusted EBITDA rose 32% to $20 million with a 41% margin. Near-flat cost of revenue, service-fee increases, growth in the points business, lower tax expense, and a favorable foreign-exchange swing supported the quarter, though first-half net income and adjusted EBITDA remained below prior-year levels.
TradingKey
Thu, Aug 13
AIRO Q2 2026 Earnings: Drone Mix Lifts Gross Margin to 64%
AIRO Group Holdings’ Q2 2026 revenue rose 76% to $43.2 million, while diluted EPS moved to a $0.06 loss from $0.30 of earnings a year earlier. A favorable shift toward higher-margin drone products lifted gross margin to 64% and returned the company to operating profitability, even as GAAP net income turned negative because prior-year other-income benefits did not recur and current tax expense exceeded pretax income. AIRO also reiterated its full-year 2026 revenue-growth and adjusted EBITDA outlook without changes.TradingKey
Thu, Aug 13
Featured Tools
Top News
Meta Q3 Net Profit Surges 264% YoY, Raises Full-Year Capex Slightly; Shares Briefly Rise Over 4% After Hours
US Stocks Close: Nasdaq Drops 2.6%, SOX Falls Over 6%; Jensen Huang's Remarks on Capital Shortage Spark Financing Concerns, Meta Drops 7% After Earnings
Bloom Energy Q3 Revenue Up 138% YoY, EPS Swings to Profit, But Shares Tumble 7% After Hours
Today’s Market Recap: Nasdaq Drops 2.60%, Meta Slumps 7%, Oil Surges Past $113, Gold Plunges Toward $4,000
Memory Stocks Fall Over 4% as Micron Drops Below $900, Risking Another 16% Fall to Retest Lows
